Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Viridian Therapeutics (NASDAQ: VRDN) is scheduled to release its Q2 2025 earnings results on August 14th, with analysts expecting earnings of (1.01) per share and revenues of $0.05 million.
• The company's previous quarter saw a reported EPS of (1.00), meeting expectations, with revenues slightly above estimates at $0.08 million.
• Wall Street maintains a consensus rating of "Moderate Buy" for VRDN, with target prices ranging from $27.00 to $38.00.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Viridian Therapeutics to post earnings of ($1.01) per share and revenue of $0.05 million for the quarter.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.00). The firm had revenue of $0.08 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 72.85% and a negative net margin of 112,806.88%. Viridian Therapeutics's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.81) EPS. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Stock Down 0.7%

NASDAQ VRDN traded down $0.12 on Friday, reaching $16.41. The company had a trading volume of 879,632 shares, compared to its average volume of 702,380. The firm has a market capitalization of $1.34 billion, a PE ratio of -4.28 and a beta of 0.42. The company has a debt-to-equity ratio of 0.05, a current ratio of 19.49 and a quick ratio of 19.49. The firm has a 50-day moving average of $15.95 and a 200-day moving average of $15.19. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $27.20.

Hedge Funds Weigh In On Viridian Therapeutics

Several large investors have recently added to or reduced their stakes in VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock worth $669,000 after buying an additional 876 shares during the period. Goldman Sachs Group Inc. increased its position in Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company's stock worth $16,595,000 after buying an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Viridian Therapeutics by 12.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company's stock worth $1,760,000 after buying an additional 14,788 shares during the period. Envestnet Asset Management Inc. acquired a new stake in Viridian Therapeutics in the second quarter worth $187,000. Finally, Creative Planning acquired a new stake in Viridian Therapeutics in the second quarter worth $179,000.

Analyst Ratings Changes

Several equities analysts have recently commented on VRDN shares. Royal Bank Of Canada reduced their target price on Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a research note on Thursday. Oppenheimer increased their target price on Viridian Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Thursday. JMP Securities reduced their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, Wells Fargo & Company reduced their target price on Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating for the company in a research note on Thursday. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $37.00.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.